Diagnostic Imaging
CONTINUE TO SITE

OR WAIT null SECS

Advertisement
Diagnostic Imaging
Spotlight
Disease Spotlight: Prostate CancerRSNA CoverageCTImage IQ Quiz
Topics
View MoreMRICTUltrasoundMammographyX-RayFacility ManagementAIView More
News
All NewsBlogs
Media
Around the Practice Between the LinesImage IQMedical World NewsPodcastsVideos
Conferences
Conference CoverageConference Listing
DI Executive
Resources
CME/CEE-booksEducationPartnersSponsored
Subscribe
eNewsletter

  • Advertise
  • Contact Us
  • Editorial
  • Editorial Board
  • Do Not Sell My Personal Information
  • Privacy
  • Terms and Conditions
  • MJHLS Brand Logo

© 2023 MJH Life Sciences and Diagnostic Imaging. All rights reserved.

Advertisement
Spotlight
  • Disease Spotlight: Prostate Cancer
  • RSNA Coverage
  • CT
  • Image IQ Quiz
TopicsSee All >
  • MRI
  • CT
  • Ultrasound
  • Mammography
  • X-Ray
  • Facility Management
  • AI
  • View More
  • Advertise
  • Contact Us
  • Editorial
  • Editorial Board
  • Do Not Sell My Personal Information
  • Privacy
  • Terms and Conditions
  • MJHLS Brand Logo

© 2023 MJH Life Sciences™ and Diagnostic Imaging. All rights reserved.

Between the Lines


18F-Fluciclovine Versus 68Ga-PSMA-11 Imaging for Prostate Cancer Biochemical Recurrence

December 23rd 2021

Steven Finkelstein, MD, DABR, FACRO, and Louis J. Mazzarelli, MD, react to the article, “A Prospective Head-to-Head Comparison of 18F-Fluciclovine With 68Ga-PSMA-11 in Biochemical Recurrence of Prostate Cancer in PET/CT,” by Pernthaler B, et al.